Physician profile
Amanda Smay
NPI 1467102541
$1,288.57
in general payments reported to CMS, 2019-2025
22 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $38.08 · 2023: $507 · 2024: $209 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $228.25 | 2022-2025 | |
| Botanix Sb INC | $151.64 | 2025 | Sofdra |
| Incyte Corporation | $125.29 | 2023 | Opzelura |
| Novartis Pharmaceuticals Corporation | $111.92 | 2024-2025 | |
| Galderma Laboratories, L.P. | $86.32 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $85.77 | 2023-2024 | Ilumya |
| Amgen INC. | $58.44 | 2025 | Otezla |
| Almirall LLC | $48.13 | 2023-2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $44.36 | 2023 | |
| Mayne Pharma Commercial LLC | $41.89 | 2024-2025 | |
| Lilly USA, LLC | $41.71 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $38.17 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $34.78 | 2025 | Acthar |
| Regeneron Healthcare Solutions, INC. | $34.32 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.38 | 2023 | Spevigo |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $22.95 | 2023 | |
| Leo Pharma INC. | $21.64 | 2022 | |
| Pfizer INC. | $19.90 | 2025 | |
| Biofrontera INC. | $19.48 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $16.25 | 2023 | Jublia |
| Janssen Biotech, INC. | $14.62 | 2023 | Tremfya |
| Sebela Pharmaceuticals INC. | $14.36 | 2023 | Naftin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Smay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.